Compare CD4/CD8 tumor-infiltrating lymphocyte (TIL) counts across non-small-cell lung cancer (NSCLC) PDO 2.0 samples and IL-2 conditions to characterize immune baseline and inform subsequent assay design.
STUDY EVIDENCE
CD4/CD8 counts within CD3-positive TILs are shown for LC-1 to LC-4 at day 7 and LC-5 at day 28. The data compare IL-2 conditions within each sample and help select samples and time points for subsequent longitudinal studies.
Human NSCLC PDOs LC-1 to LC-4 show CD4 and CD8 TIL counts at d7 across IL-2 conditions, enabling comparison of sample baseline and stimulation context. Blue: CD8; yellow: CD4. The y-axis reports CD3+ TIL counts per 10⁶ total cells.
Supports comparison of samples and stimulation conditions for subsequent immune studies
LC-5 results at d28 show CD4 and CD8 TIL counts across IL-2 conditions, describing the sample's immune baseline and stimulation context at that time point. Blue: CD8; yellow: CD4. The y-axis reports CD3+ TIL counts per 10⁶ total cells.
Helps select samples and time points for subsequent longitudinal studiesIL-2 conditions and TIL readouts within each sample provide a basis for subsequent longitudinal culture, immune treatment, replication and functional-assay design.
INTERPRETATION
Identifies measurable T-cell signals and helps select samples, time points and treatment conditions for subsequent longitudinal studies.
Use CD4/CD8 counts and IL-2 conditions to compare sample immune baselines and design longitudinal culture, key time points and replication.
Set dose, time, cytokine and flow endpoints around the candidate mechanism, then compare across replicates or independent samples.
Related models and services
PROJECT DISCUSSION
Tell us which model, assay or finding you want to extend. Our scientists will adapt the approach to your candidate, samples and decision point.
Compare CD4/CD8 tumor-infiltrating lymphocyte (TIL) counts across non-small-cell lung cancer (NSCLC) PDO 2.0 samples and IL-2 conditions to characterize immune baseline and inform subsequent assay design.
STUDY EVIDENCE
CD4/CD8 counts within CD3-positive TILs are shown for LC-1 to LC-4 at day 7 and LC-5 at day 28. The data compare IL-2 conditions within each sample and help select samples and time points for subsequent longitudinal studies.
Human NSCLC PDOs LC-1 to LC-4 show CD4 and CD8 TIL counts at d7 across IL-2 conditions, enabling comparison of sample baseline and stimulation context. Blue: CD8; yellow: CD4. The y-axis reports CD3+ TIL counts per 10⁶ total cells.
Supports comparison of samples and stimulation conditions for subsequent immune studiesLC-5 results at d28 show CD4 and CD8 TIL counts across IL-2 conditions, describing the sample's immune baseline and stimulation context at that time point. Blue: CD8; yellow: CD4. The y-axis reports CD3+ TIL counts per 10⁶ total cells.
Helps select samples and time points for subsequent longitudinal studiesIL-2 conditions and TIL readouts within each sample provide a basis for subsequent longitudinal culture, immune treatment, replication and functional-assay design.
INTERPRETATION
Identifies measurable T-cell signals and helps select samples, time points and treatment conditions for subsequent longitudinal studies.
Use CD4/CD8 counts and IL-2 conditions to compare sample immune baselines and design longitudinal culture, key time points and replication.
Set dose, time, cytokine and flow endpoints around the candidate mechanism, then compare across replicates or independent samples.
Related models and services
PROJECT DISCUSSION
Tell us which model, assay or finding you want to extend. Our scientists will adapt the approach to your candidate, samples and decision point.
